论文部分内容阅读
目的探讨白蛋白联合呋塞米对肝硬化腹水的治疗效果。方法 96例肝硬化腹水患者,随机分为观察组和对照组,每组48例。对照组采用呋塞米治疗;观察组在对照组基础上加用20%人血白蛋白治疗。由专人负责对两组患者的腹胀程度、每日尿量、腹水消退时间及并发症的发生情况进行记录和整理。结果治疗结束后,观察组患者的腹胀缓解、腹水减退时间以及每日排尿量均优于对照组,而观察组各指标改善及并发症发生方面优于对照组,差异具有统计学意义(P<0.05)。结论白蛋白联合呋塞米对肝硬化腹水的治疗效果满意,不良反应发生较少,值得在今后的临床实践中进行进一步的推广和使用。
Objective To investigate the therapeutic effect of albumin combined with furosemide on ascites caused by cirrhosis. Methods 96 patients with cirrhosis and ascites were randomly divided into observation group and control group, 48 cases in each group. The control group was treated with furosemide; the observation group was treated with 20% human serum albumin on the basis of the control group. By the person responsible for the two groups of patients with abdominal distension, daily urine output, ascites extinction time and the incidence of complications were recorded and collated. Results At the end of treatment, patients in the observation group had better relief of abdominal distension, time of ascites and urinary volume per day than the control group, while the observation group was better than the control group in improving the indexes and complication. The difference was statistically significant (P < 0.05). Conclusions Albumin combined with furosemide is effective in the treatment of cirrhosis and ascites, with fewer adverse reactions. It is worth further promotion and use in future clinical practice.